Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with colorectal cancer liver metastases (CRCLM).

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with resectable CRCLM.

Inclusion Criteria:

• Patients with histologically confirmed adenocarcinoma
• Primary lesions (colorectal cancer) are resected
• Must have undergone prior complete resection of the primary tumor; liver metastases
• Must be resectable or accessible for radiofrequency ablation (Five or less lung metastases measuring 5 cm or smaller).
• Serum bilirubin level of 2.0 mg/dl or less.
• Performance status of 0 or 1.
• Expected survival of 1 year or more.
• Informed consent from the patient.

Exclusion Criteria:

• With extrahepatic metastases
• With other neoplastic disease that is measurable or being treated other than colorectal cancer.